A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Biliary Tract Neoplasms

abstract

  • The addition of sorafenib to gemcitabine and cisplatin in biliary adenocarcinomas did not improve efficacy over historical data, and toxicity was increased.

publication date

  • August 20, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3749586

Digital Object Identifier (DOI)

  • 10.1038/bjc.2013.432

PubMed ID

  • 23900219

Additional Document Info

start page

  • 915

end page

  • 9

volume

  • 109

number

  • 4